Co-factors in liver disease: The role of HFE-related hereditary hemochromatosis and iron

Biochimica et Biophysica Acta - General Subjects

Volumn 1790, Issue 7, 2009, Pages 663-670

  Wallace, Daniel F ^a   Subramaniam, V Nathan ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Alcohol; Hemochromatosis; Hepatitis; Iron; Liver; Porphyria cutanea tarda

Indexed keywords

HFE PROTEIN; IRON;

ALCOHOL LIVER DISEASE; CLINICAL FEATURE; DISEASE MODEL; DISEASE SEVERITY; DUODENUM; GENE MUTATION; GENETIC DISORDER; HEMOCHROMATOSIS; HEPATITIS C; HETEROZYGOSITY; HOMEOSTASIS; HOMOZYGOSITY; HUMAN; IRON ABSORPTION; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FAILURE; LIVER INJURY; MACROPHAGE; METABOLIC DISORDER; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PORPHYRIA CUTANEA TARDA; PRIORITY JOURNAL; REVIEW;

CARCINOMA, HEPATOCELLULAR; FATTY LIVER; HEMOCHROMATOSIS; HEPATITIS C, CHRONIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HOMEOSTASIS; HUMANS; IRON; IRON METABOLISM DISORDERS; LIVER DISEASES; LIVER DISEASES, ALCOHOLIC; LIVER NEOPLASMS; MEMBRANE PROTEINS; PORPHYRIA CUTANEA TARDA;

HEPATITIS C VIRUS;

EID: 67349267809     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2008.09.002     Document Type: Review

References (148)

1. Zhou X.Y., Tomatsu S., Fleming R.E., Parkkila S., Waheed A., Jiang J., Fei Y., Brunt E.M., Ruddy D.A., Prass C.E., Schatzman R.C., O'Neill R., Britton R.S., Bacon B.R., and Sly W.S. HFE gene knockout produces mouse model of hereditary hemochromatosis. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 2492-2497
2. Fleming R.E., Ahmann J.R., Migas M.C., Waheed A., Koeffler H.P., Kawabata H., Britton R.S., Bacon B.R., and Sly W.S. Targeted mutagenesis of the murine transferrin receptor-2 gene produces hemochromatosis. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 10653-10658
3. Wallace D.F., Summerville L., Lusby P.E., and Subramaniam V.N. First phenotypic description of transferrin receptor 2 knockout mouse, and the role of hepcidin. Gut 54 (2005) 980-986
4. Huang F.W., Pinkus J.L., Pinkus G.S., Fleming M.D., and Andrews N.C. A mouse model of juvenile hemochromatosis. J. Clin. Invest. 115 (2005) 2187-2191
5. Niederkofler V., Salie R., and Arber S. Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload. J. Clin. Invest. 115 (2005) 2180-2186
6. Lesbordes-Brion J.C., Viatte L., Bennoun M., Lou D.Q., Ramey G., Houbron C., Hamard G., Kahn A., and Vaulont S. Targeted disruption of the hepcidin 1 gene results in severe hemochromatosis. Blood 108 (2006) 1402-1405
7. Zohn I.E., De Domenico I., Pollock A., Ward D.M., Goodman J.F., Liang X., Sanchez A.J., Niswander L., and Kaplan J. The flatiron mutation in mouse ferroportin acts as a dominant negative to cause ferroportin disease. Blood 109 (2007) 4174-4180
8. Nicolas G., Bennoun M., Porteu A., Mativet S., Beaumont C., Grandchamp B., Sirito M., Sawadogo M., Kahn A., and Vaulont S. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 4596-4601
9. Wallace D.F., Summerville L., and Subramaniam V.N. Targeted disruption of the hepatic transferrin receptor 2 gene in mice leads to iron overload. Gastroenterology 132 (2007) 301-310
10. Vujic Spasic M., Kiss J., Herrmann T., Galy B., Martinache S., Stolte J., Grone H.J., Stremmel W., Hentze M.W., and Muckenthaler M.U. Hfe acts in hepatocytes to prevent hemochromatosis. Cell. Metab. 7 (2008) 173-178
11. Vujic Spasic M., Kiss J., Herrmann T., Kessler R., Stolte J., Galy B., Rathkolb B., Wolf E., Stremmel W., Hentze M.W., and Muckenthaler M.U. Physiologic systemic iron metabolism in mice deficient for duodenal Hfe. Blood 109 (2007) 4511-4517
12. Pigeon C., Ilyin G., Courselaud B., Leroyer P., Turlin B., Brissot P., and Loreal O. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J. Biol. Chem. 276 (2001) 7811-7819
13. Nicolas G., Chauvet C., Viatte L., Danan J.L., Bigard X., Devaux I., Beaumont C., Kahn A., and Vaulont S. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J. Clin. Invest. 110 (2002) 1037-1044
14. Laftah A.H., Ramesh B., Simpson R.J., Solanky N., Bahram S., Schumann K., Debnam E.S., and Srai S.K. Effect of hepcidin on intestinal iron absorption in mice. Blood 103 (2004) 3940-3944
15. Rivera S., Nemeth E., Gabayan V., Lopez M.A., Farshidi D., and Ganz T. Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood 106 (2005) 2196-2199
16. Nemeth E., Tuttle M.S., Powelson J., Vaughn M.B., Donovan A., Ward D.M., Ganz T., and Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306 (2004) 2090-2093
17. Feder J.N., Gnirke A., Thomas W., Tsuchihashi Z., Ruddy D.A., Basava A., Dormishian F., Domingo Jr. R., Ellis M.C., Fullan A., Hinton L.M., Jones N.L., Kimmel B.E., Kronmal G.S., Lauer P., Lee V.K., Loeb D.B., Mapa F.A., McClelland E., Meyer N.C., Mintier G.A., Moeller N., Moore T., Morikang E., Prass C.E., Quintana L., Starnes S.M., Schatzman R.C., Brunke K.J., Drayna D.T., Risch N.J., Bacon B.R., and Wolff R.K. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat. Genet. 13 (1996) 399-408
18. Merryweather-Clarke A.T., Pointon J.J., Jouanolle A.M., Rochette J., and Robson K.J. Geography of HFE C282Y and H63D mutations. Genet. Test 4 (2000) 183-198
19. Beutler E. The significance of the 187G (H63D) mutation in hemochromatosis. Am. J. Hum. Genet. 61 (1997) 762-764
20. Jackson H.A., Carter K., Darke C., Guttridge M.G., Ravine D., Hutton R.D., Napier J.A., and Worwood M. HFE mutations, iron deficiency and overload in 10,500 blood donors. Br. J. Haematol. 114 (2001) 474-484
21. Beutler E., Felitti V.J., Koziol J.A., Ho N.J., and Gelbart T. Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 359 (2002) 211-218
22. Allen K.J., Gurrin L.C., Constantine C.C., Osborne N.J., Delatycki M.B., Nicoll A.J., McLaren C.E., Bahlo M., Nisselle A.E., Vulpe C.D., Anderson G.J., Southey M.C., Giles G.G., English D.R., Hopper J.L., Olynyk J.K., Powell L.W., and Gertig D.M. Iron-overload-related disease in HFE hereditary hemochromatosis. N. Engl. J. Med. 358 (2008) 221-230
23. Roetto A., Papanikolaou G., Politou M., Alberti F., Girelli D., Christakis J., Loukopoulos D., and Camaschella C. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat. Genet. 33 (2003) 21-22
24. Papanikolaou G., Samuels M.E., Ludwig E.H., MacDonald M.L., Franchini P.L., Dube M.P., Andres L., MacFarlane J., Sakellaropoulos N., Politou M., Nemeth E., Thompson J., Risler J.K., Zaborowska C., Babakaiff R., Radomski C.C., Pape T.D., Davidas O., Christakis J., Brissot P., Lockitch G., Ganz T., Hayden M.R., and Goldberg Y.P. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat. Genet. 36 (2004) 77-82
25. Camaschella C., Roetto A., Cali A., De Gobbi M., Garozzo G., Carella M., Majorano N., Totaro A., and Gasparini P. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat. Genet. 25 (2000) 14-15
26. Njajou O.T., Vaessen N., Joosse M., Berghuis B., van Dongen J.W., Breuning M.H., Snijders P.J., Rutten W.P., Sandkuijl L.A., Oostra B.A., van Duijn C.M., and Heutink P. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat. Genet. 28 (2001) 213-214
27. Montosi G., Donovan A., Totaro A., Garuti C., Pignatti E., Cassanelli S., Trenor C.C., Gasparini P., Andrews N.C., and Pietrangelo A. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J. Clin. Invest. 108 (2001) 619-623
28. Pietrangelo A. The ferroportin disease. Blood Cells Mol. Dis. 32 (2004) 131-138
29. Bottomley S.S. Secondary iron overload disorders. Semin. Hematol. 35 (1998) 77-86
30. Powell L.W. Hereditary hemochromatosis and iron overload diseases. J. Gastroenterol. Hepatol. 17 Suppl (2002) S191-S195
31. Wood M.J., Powell L.W., and Ramm G.A. Environmental and genetic modifiers of the progression to fibrosis and cirrhosis in hemochromatosis. Blood 111 (2008) 4456-4462
32. Ramm G.A., Crawford D.H., Powell L.W., Walker N.I., Fletcher L.M., and Halliday J.W. Hepatic stellate cell activation in genetic haemochromatosis. Lobular distribution, effect of increasing hepatic iron and response to phlebotomy. J. Hepatol. 26 (1997) 584-592
33. Bridle K.R., Crawford D.H., Fletcher L.M., Smith J.L., Powell L.W., and Ramm G.A. Evidence for a sub-morphological inflammatory process in the liver in haemochromatosis. J. Hepatol. 38 (2003) 426-433
34. Bulaj Z.J., Ajioka R.S., Phillips J.D., LaSalle B.A., Jorde L.B., Griffen L.M., Edwards C.Q., and Kushner J.P. Disease-related conditions in relatives of patients with hemochromatosis. N. Engl. J. Med. 343 (2000) 1529-1535
35. Powell L.W., Dixon J.L., Ramm G.A., Purdie D.M., Lincoln D.J., Anderson G.J., Subramaniam V.N., Hewett D.G., Searle J.W., Fletcher L.M., Crawford D.H., Rodgers H., Allen K.J., Cavanaugh J.A., and Bassett M.L. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch. Intern. Med. 166 (2006) 294-301
36. Asberg A., Hveem K., Kannelonning K., and Irgens W.O. Penetrance of the C28Y/C282Y genotype of the HFE gene. Scand. J. Gastroenterol. 42 (2007) 1073-1077
37. Kattamis A., Papassotiriou I., Palaiologou D., Apostolakou F., Galani A., Ladis V., Sakellaropoulos N., and Papanikolaou G. The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major. Haematologica 91 (2006) 809-812
38. Bonkovsky H.L., Lambrecht R.W., and Shan Y. Iron as a co-morbid factor in nonhemochromatotic liver disease. Alcohol 30 (2003) 137-144
39. Bulaj Z.J., Griffen L.M., Jorde L.B., Edwards C.Q., and Kushner J.P. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N. Engl. J. Med. 335 (1996) 1799-1805
40. Beutler E. Genetic irony beyond haemochromatosis: clinical effects of HLA-H mutations. Lancet 349 (1997) 296-297
41. Alter M.J., Kruszon-Moran D., Nainan O.V., McQuillan G.M., Gao F., Moyer L.A., Kaslow R.A., and Margolis H.S. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. 341 (1999) 556-562
42. Rosenberg W. Mechanisms of immune escape in viral hepatitis. Gut 44 (1999) 759-764
43. Di Bisceglie A.M. Hepatitis C. Lancet 351 (1998) 351-355
44. Di Bisceglie A.M., Axiotis C.A., Hoofnagle J.H., and Bacon B.R. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 102 (1992) 2108-2113
45. Farinati F., Cardin R., De Maria N., Della Libera G., Marafin C., Lecis E., Burra P., Floreani A., Cecchetto A., and Naccarato R. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J. Hepatol. 22 (1995) 449-456
46. Piperno A., D'Alba R., Fargion S., Roffi L., Sampietro M., Parma S., Arosio V., Fare M., and Fiorelli G. Liver iron concentration in chronic viral hepatitis: a study of 98 patients. Eur. J. Gastroenterol. Hepatol. 7 (1995) 1203-1208
47. Hayashi H., Takikawa T., Nishimura N., Yano M., Isomura T., and Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am. J. Gastroenterol. 89 (1994) 986-988
48. Kawamura Y., Akuta N., Sezaki H., Hosaka T., Someya T., Kobayashi M., Suzuki F., Suzuki Y., Saitoh S., Arase Y., Ikeda K., and Kumada H. Determinants of serum ALT normalization after phlebotomy in patients with chronic hepatitis C infection. J. Gastroenterol. 40 (2005) 901-906
49. Alexander J., Tung B.Y., Croghan A., and Kowdley K.V. Effect of iron depletion on serum markers of fibrogenesis, oxidative stress and serum liver enzymes in chronic hepatitis C: results of a pilot study. Liver Int. 27 (2007) 268-273
50. Kato J., Miyanishi K., Kobune M., Nakamura T., Takada K., Takimoto R., Kawano Y., Takahashi S., Takahashi M., Sato Y., Takayama T., and Niitsu Y. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J. Gastroenterol. 42 (2007) 830-836
51. Okuda M., Li K., Beard M.R., Showalter L.A., Scholle F., Lemon S.M., and Weinman S.A. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 122 (2002) 366-375
52. Smith B.C., Gorve J., Guzail M.A., Day C.P., Daly A.K., Burt A.D., and Bassendine M.F. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 27 (1998) 1695-1699
53. Martinelli A.L., Franco R.F., Villanova M.G., Figueiredo J.F., Secaf M., Tavella M.H., Ramalho L.N., Zucoloto S., and Zago M.A. Are haemochromatosis mutations related to the severity of liver disease in hepatitis C virus infection?. Acta Haematol. 102 (2000) 152-156
54. Bonkovsky H.L., Troy N., McNeal K., Banner B.F., Sharma A., Obando J., Mehta S., Koff R.S., Liu Q., and Hsieh C.C. Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C. J. Hepatol. 37 (2002) 848-854
55. Tung B.Y., Emond M.J., Bronner M.P., Raaka S.D., Cotler S.J., and Kowdley K.V. Hepatitis C, iron status, and disease severity: relationship with HFE mutations. Gastroenterology 124 (2003) 318-326
56. Erhardt A., Maschner-Olberg A., Mellenthin C., Kappert G., Adams O., Donner A., Willers R., Niederau C., and Haussinger D. HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis. J. Hepatol. 38 (2003) 335-342
57. Corengia C., Galimberti S., Bovo G., Vergani A., Arosio C., Mariani R., Redaelli A., Riva A., Cestari C., Pozzi M., Valsecchi M.G., and Piperno A. Iron accumulation in chronic hepatitis C: relation of hepatic iron distribution, HFE genotype, and disease course. Am. J. Clin. Pathol. 124 (2005) 846-853
58. Pacal L., Husa P., Znojil V., and Kankova K. HFE C282Y gene variant is a risk factor for the progression to decompensated liver disease in chronic viral hepatitis C subjects in the Czech population. Hepatol. Res. 37 (2007) 740-747
59. Kazemi-Shirazi L., Datz C., Maier-Dobersberger T., Kaserer K., Hackl F., Polli C., Steindl P.E., Penner E., and Ferenci P. The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C. Gastroenterology 116 (1999) 127-134
60. Hezode C., Cazeneuve C., Coue O., Roudot-Thoraval F., Lonjon I., Bastie A., Duvoux C., Pawlotsky J.M., Zafrani E.S., Amselem S., and Dhumeaux D. Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions. J. Hepatol. 31 (1999) 979-984
61. Negro F., Samii K., Rubbia-Brandt L., Quadri R., Male P.J., Zarski J.P., Baud M., Giostra E., Beris P., and Hadengue A. Hemochromatosis gene mutations in chronic hepatitis C patients with and without liver siderosis. J. Med. Virol. 60 (2000) 21-27
62. Distante S., Bjoro K., Hellum K.B., Myrvang B., Berg J.P., Skaug K., Raknerud N., and Bell H. Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. Liver 22 (2002) 269-275
63. Thorburn D., Curry G., Spooner R., Spence E., Oien K., Halls D., Fox R., McCruden E.A., MacSween R.N., and Mills P.R. The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut 50 (2002) 248-252
64. Lebray P., Zylberberg H., Hue S., Poulet B., Carnot F., Martin S., Chretien Y., Pol S., Caillat-Zuckman S., Brechot C., and Nalpas B. Influence of HFE gene polymorphism on the progression and treatment of chronic hepatitis C. J. Viral Hepat. 11 (2004) 175-182
65. Bonkovsky H.L., Naishadham D., Lambrecht R.W., Chung R.T., Hoefs J.C., Nash S.R., Rogers T.E., Banner B.F., Sterling R.K., Donovan J.A., Fontana R.J., Di Bisceglie A.M., Ghany M.G., and Morishima C. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology 131 (2006) 1440-1451
66. Furutani T., Hino K., Okuda M., Gondo T., Nishina S., Kitase A., Korenaga M., Xiao S.Y., Weinman S.A., Lemon S.M., Sakaida I., and Okita K. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 130 (2006) 2087-2098
67. Nishina S., Hino K., Korenaga M., Vecchi C., Pietrangelo A., Mizukami Y., Furutani T., Sakai A., Okuda M., Hidaka I., Okita K., and Sakaida I. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology 134 (2008) 226-238
68. Fujita N., Sugimoto R., Takeo M., Urawa N., Mifuji R., Tanaka H., Kobayashi Y., Iwasa M., Watanabe S., Adachi Y., and Kaito M. Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C. Mol. Med. 13 (2007) 97-104
69. Day C.P., and Bassendine M.F. Genetic predisposition to alcoholic liver disease. Gut 33 (1992) 1444-1447
70. Harrison-Findik D.D. Role of alcohol in the regulation of iron metabolism. World J. Gastroenterol. 13 (2007) 4925-4930
71. Ioannou G.N., Dominitz J.A., Weiss N.S., Heagerty P.J., and Kowdley K.V. The effect of alcohol consumption on the prevalence of iron overload, iron deficiency, and iron deficiency anemia. Gastroenterology 126 (2004) 1293-1301
72. Ludwig J., Hashimoto E., Porayko M.K., Moyer T.P., and Baldus W.P. Hemosiderosis in cirrhosis: a study of 447 native livers. Gastroenterology 112 (1997) 882-888
73. Eng S.C., Taylor S.L., Reyes V., Raaka S., Berger J., and Kowdley K.V. Hepatic iron overload in alcoholic end-stage liver disease is associated with iron deposition in other organs in the absence of HFE-1 hemochromatosis. Liver Int. 25 (2005) 513-517
74. Fargion S., Fracanzani A.L., Piperno A., Braga M., D'Alba R., Ronchi G., and Fiorelli G. Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis. Hepatology 20 (1994) 1426-1431
75. Adams P.C., and Agnew S. Alcoholism in hereditary hemochromatosis revisited: prevalence and clinical consequences among homozygous siblings. Hepatology 23 (1996) 724-727
76. Fletcher L.M., Dixon J.L., Purdie D.M., Powell L.W., and Crawford D.H.G. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology 122 (2002) 281-289
77. Scotet V., Merour M.C., Mercier A.Y., Chanu B., Le Faou T., Raguenes O., Le Gac G., Mura C., Nousbaum J.B., and Ferec C. Hereditary hemochromatosis: effect of excessive alcohol consumption on disease expression in patients homozygous for the C282Y mutation. Am. J. Epidemiol. 158 (2003) 129-134
78. Walsh A., Dixon J.L., Ramm G.A., Hewett D.G., Lincoln D.J., Anderson G.J., Subramaniam V.N., Dodemaide J., Cavanaugh J.A., Bassett M.L., and Powell L.W. The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in hemochromatosis. Clin. Gastroenterol. Hepatol. 4 (2006) 1403-1410
79. Grove J., Daly A.K., Burt A.D., Guzail M., James O.F., Bassendine M.F., and Day C.P. Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease. Gut 43 (1998) 262-266
80. Gleeson D., Evans S., Bradley M., Jones J., Peck R.J., Dube A., Rigby E., and Dalton A. HFE genotypes in decompensated alcoholic liver disease: phenotypic expression and comparison with heavy drinking and with normal controls. Am. J. Gastroenterol. 101 (2006) 304-310
81. Lauret E., Rodriguez M., Gonzalez S., Linares A., Lopez-Vazquez A., Martinez-Borra J., Rodrigo L., and Lopez-Larrea C. HFE gene mutations in alcoholic and virus-related cirrhotic patients with hepatocellular carcinoma. Am. J. Gastroenterol. 97 (2002) 1016-1021
82. Frenzer A., Rudzki Z., Norton I.D., Butler W.J., and Roberts-Thomson I.C. Heterozygosity of the haemochromatosis mutation, C282Y, does not influence susceptibility to alcoholic cirrhosis. Scand. J. Gastroenterol. 33 (1998) 1324
83. Robinson G., Narasimhan S., Weatherall M., and Beasley R. Hemochromatosis gene mutations, liver function tests and iron status in alcohol-dependent patients admitted for detoxification. J. Gastroenterol. Hepatol. 22 (2007) 852-854
84. Ropero Gradilla P., Villegas Martinez A., Fernandez Arquero M., Garcia-Agundez J.A., Gonzalez Fernandez F.A., Benitez Rodriguez J., Diaz-Rubio M., de la Concha E.G., and Ladero Quesada J.M. C282Y and H63D mutations of HFE gene in patients with advanced alcoholic liver disease. Rev. Esp. Enferm. Dig. 93 (2001) 156-163
85. Flanagan J.M., Peng H., and Beutler E. Effects of alcohol consumption on iron metabolism in mice with hemochromatosis mutations. Alcohol Clin. Exp. Res. 31 (2007) 138-143
86. Bridle K., Cheung T.K., Murphy T., Walters M., Anderson G., Crawford D.H.G., and Fletcher L.M. Hepcidin is down-regulated in alcoholic liver injury: implications for the pathogenesis of alcoholic liver disease. Alcohol Clin. Exp. Res. 30 (2006) 106-112
87. Harrison-Findik D.D., Schafer D., Klein E., Timchenko N.A., Kulaksiz H., Clemens D., Fein E., Andriopoulos B., Pantopoulos K., and Gollan J. Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression. J. Biol. Chem. 281 (2006) 22974-22982
88. Harrison-Findik D.D., Klein E., Crist C., Evans J., Timchenko N., and Gollan J. Iron-mediated regulation of liver hepcidin expression in rats and mice is abolished by alcohol. Hepatology 46 (2007) 1979-1985
89. Matteoni C.A., Younossi Z.M., Gramlich T., Boparai N., Liu Y.C., and McCullough A.J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116 (1999) 1413-1419
90. Caldwell S.H., Oelsner D.H., Iezzoni J.C., Hespenheide E.E., Battle E.H., and Driscoll C.J. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 29 (1999) 664-669
91. Day C.P., and James O.F. Steatohepatitis: a tale of two "hits"?. Gastroenterology 114 (1998) 842-845
92. Fargion S., Mattioli M., Fracanzani A.L., Sampietro M., Tavazzi D., Fociani P., Taioli E., Valenti L., and Fiorelli G. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am. J. Gastroenterol. 96 (2001) 2448-2455
93. Bugianesi E., Manzini P., D'Antico S., Vanni E., Longo F., Leone N., Massarenti P., Piga A., Marchesini G., and Rizzetto M. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 39 (2004) 179-187
94. George D.K., Goldwurm S., MacDonald G.A., Cowley L.L., Walker N.I., Ward P.J., Jazwinska E.C., and Powell L.W. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 114 (1998) 311-318
95. Mendler M.H., Turlin B., Moirand R., Jouanolle A.M., Sapey T., Guyader D., Le Gall J.Y., Brissot P., David V., and Deugnier Y. Insulin resistance-associated hepatic iron overload. Gastroenterology 117 (1999) 1155-1163
96. Facchini F.S., Hua N.W., and Stoohs R.A. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 122 (2002) 931-939
97. Valenti L., Fracanzani A.L., Dongiovanni P., Bugianesi E., Marchesini G., Manzini P., Vanni E., and Fargion S. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am. J. Gastroenterol. 102 (2007) 1251-1258
98. Bonkovsky H.L., Jawaid Q., Tortorelli K., LeClair P., Cobb J., Lambrecht R.W., and Banner B.F. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J. Hepatol. 31 (1999) 421-429
99. Nelson J.E., Bhattacharya R., Lindor K.D., Chalasani N., Raaka S., Heathcote E.J., Miskovsky E., Shaffer E., Rulyak S.J., and Kowdley K.V. HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology 46 (2007) 723-729
100. Chitturi S., Weltman M., Farrell G.C., McDonald D., Kench J., Liddle C., Samarasinghe D., Lin R., Abeygunasekera S., and George J. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 36 (2002) 142-149
101. Deguti M.M., Sipahi A.M., Gayotto L.C., Palacios S.A., Bittencourt P.L., Goldberg A.C., Laudanna A.A., Carrilho F.J., and Cancado E.L. Lack of evidence for the pathogenic role of iron and HFE gene mutations in Brazilian patients with nonalcoholic steatohepatitis. Braz. J. Med. Biol. Res. 36 (2003) 739-745
102. Le Guenno G., Chanseaume E., Ruivard M., Morio B., and Mazur A. Study of iron metabolism disturbances in an animal model of insulin resistance. Diabetes Res. Clin. Pract. 77 (2007) 363-370
103. Cotler S.J., Bronner M.P., Press R.D., Carlson T.H., Perkins J.D., Emond M.J., and Kowdley K.V. End-stage liver disease without hemochromatosis associated with elevated hepatic iron index. J. Hepatol. 29 (1998) 257-262
104. Alanen K.W., Chakrabarti S., Rawlins J.J., Howson W., Jeffrey G., and Adams P.C. Prevalence of the C282Y mutation of the hemochromatosis gene in liver transplant recipients and donors. Hepatology 30 (1999) 665-669
105. Fiel M.I., Schiano T.D., Bodenheimer H.C., Thung S.N., King T.W., Varma C.R., Miller C.M., Brunt E.M., Starnes S., Prass C., Wolff R.K., and Bacon B.R. Hereditary hemochromatosis in liver transplantation. Liver Transpl. Surg. 5 (1999) 50-56
106. Ko C., Siddaiah N., Berger J., Gish R., Brandhagen D., Sterling R.K., Cotler S.J., Fontana R.J., McCashland T.M., Han S.H., Gordon F.D., Schilsky M.L., and Kowdley K.V. Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry. Liver Int. 27 (2007) 1394-1401
107. Niederau C., Fischer R., Purschel A., Stremmel W., Haussinger D., and Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 110 (1996) 1107-1119
108. Tomao S., Romiti A., Mozzicafreddo A., Raffaele M., Zullo A., and Antonaci A. Onset of hepatocellular carcinoma in a non-cirrhotic patient affected with haemochromatosis. Oncol. Rep. 5 (1998) 723-725
109. Goh J., Callagy G., McEntee G., O'Keane J.C., Bomford A., and Crowe J. Hepatocellular carcinoma arising in the absence of cirrhosis in genetic haemochromatosis: three case reports and review of literature. Eur. J. Gastroenterol. Hepatol. 11 (1999) 915-919
110. Kohler H.H., Hohler T., Kusel U., Kirkpatrick C.J., and Schirmacher P. Hepatocellular carcinoma in a patient with hereditary hemochromatosis and noncirrhotic liver. A case report. Pathol. Res. Pract. 195 (1999) 509-513
111. Bralet M.P., Regimbeau J.M., Pineau P., Dubois S., Loas G., Degos F., Valla D., Belghiti J., Degott C., and Terris B. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology 32 (2000) 200-204
112. Asare G.A., Paterson A.C., Kew M.C., Khan S., and Mossanda K.S. Iron-free neoplastic nodules and hepatocellular carcinoma without cirrhosis in Wistar rats fed a diet high in iron. J. Pathol. 208 (2006) 82-90
113. Lehmann U., Wingen L.U., Brakensiek K., Wedemeyer H., Becker T., Heim A., Metzig K., Hasemeier B., Kreipe H., and Flemming P. Epigenetic defects of hepatocellular carcinoma are already found in non-neoplastic liver cells from patients with hereditary haemochromatosis. Hum. Mol. Genet. 16 (2007) 1335-1342
114. Beckman L.E., Hagerstrand I., Stenling R., Van Landeghem G.F., and Beckman L. Interaction between haemochromatosis and transferrin receptor genes in hepatocellular carcinoma. Oncology 59 (2000) 317-322
115. Blanc J.F., De Ledinghen V., Bernard P.H., de Verneuil H., Winnock M., Le Bail B., Carles J., Saric J., Balabaud C., and Bioulac-Sage P. Increased incidence of HFE C282Y mutations in patients with iron overload and hepatocellular carcinoma developed in non-cirrhotic liver. J. Hepatol. 32 (2000) 805-811
116. Fargion S., Stazi M.A., Fracanzani A.L., Mattioli M., Sampietro M., Tavazzi D., Bertelli C., Patriarca V., Mariani C., and Fiorelli G. Mutations in the HFE gene and their interaction with exogenous risk factors in hepatocellular carcinoma. Blood Cells Mol. Dis. 27 (2001) 505-511
117. Boige V., Castera L., de Roux N., Ganne-Carrie N., Ducot B., Pelletier G., Beaugrand M., and Buffet C. Lack of association between HFE gene mutations and hepatocellular carcinoma in patients with cirrhosis. Gut 52 (2003) 1178-1181
118. Hellerbrand C., Poppl A., Hartmann A., Scholmerich J., and Lock G. HFE C282Y heterozygosity in hepatocellular carcinoma: evidence for an increased prevalence. Clin. Gastroenterol. Hepatol. 1 (2003) 279-284
119. Nahon P., Sutton A., Rufat P., Ziol M., Thabut G., Schischmanoff P.O., Vidaud D., Charnaux N., Couvert P., Ganne-Carrie N., Trinchet J.C., Gattegno L., and Beaugrand M. Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis. Gastroenterology 134 (2008) 102-110
120. Kushner J.P., Barbuto A.J., and Lee G.R. An inherited enzymatic defect in porphyria cutanea tarda: decreased uroporphyrinogen decarboxylase activity. J. Clin. Invest. 58 (1976) 1089-1097
121. Mendez M., Sorkin L., Rossetti M.V., Astrin K.H., del C.B.A.M., Parera V.E., Aizencang G., and Desnick R.J. Familial porphyria cutanea tarda: characterization of seven novel uroporphyrinogen decarboxylase mutations and frequency of common hemochromatosis alleles. Am. J. Hum. Genet. 63 (1998) 1363-1375
122. Rossmann-Ringdahl I., and Olsson R. Porphyria cutanea tarda in a Swedish population: risk factors and complications. Acta Derm. Venereol. 85 (2005) 337-341
123. Mendez M., Rossetti M.V., Del C.B.A.M., and Parera V.E. The role of inherited and acquired factors in the development of porphyria cutanea tarda in the Argentinean population. J. Am. Acad. Dermatol. 52 (2005) 417-424
124. Turnbull A., Baker H., Vernon-Roberts B., and Magnus I.A. Iron metabolism in porphyria cutanea tarda and in erythropoietic protoporphyria. Q. J. Med. 42 (1973) 341-355
125. Epstein J.H., and Redeker A.G. Porphyria cutanea tarda. A study of the effect of phlebotomy. N. Engl. J. Med. 279 (1968) 1301-1304
126. Ramsay C.A., Magnus I.A., Turnbull A., and Baker H. The treatment of porphyria cutanea tarda by venesection. Q. J. Med. 43 (1974) 1-24
127. Kushner J.P., Edwards C.Q., Dadone M.M., and Skolnick M.H. Heterozygosity for HLA-linked hemochromatosis as a likely cause of the hepatic siderosis associated with sporadic porphyria cutanea tarda. Gastroenterology 88 (1985) 1232-1238
128. Roberts A.G., Whatley S.D., Morgan R.R., Worwood M., and Elder G.H. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet 349 (1997) 321-323
129. Stuart K.A., Busfield F., Jazwinska E.C., Gibson P., Butterworth L.A., Cooksley W.G., Powell L.W., and Crawford D.H.G. The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients. J. Hepatol. 28 (1998) 404-409
130. Santos M., Clevers H.C., and Marx J.J. Mutations of the hereditary hemochromatosis candidate gene HLA-H in porphyria cutanea tarda. N. Engl. J. Med. 336 (1997) 1327-1328
131. Bonkovsky H.L., Poh-Fitzpatrick M., Pimstone N., Obando J., Di Bisceglie A., Tattrie C., Tortorelli K., LeClair P., Mercurio M.G., and Lambrecht R.W. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 27 (1998) 1661-1669
132. Bulaj Z.J., Phillips J.D., Ajioka R.S., Franklin M.R., Griffen L.M., Guinee D.J., Edwards C.Q., and Kushner J.P. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood 95 (2000) 1565-1571
133. Martinelli A.L., Zago M.A., Roselino A.M., Filho A.B., Villanova M.G., Secaf M., Tavella M.H., Ramalho L.N., Zucoloto S., and Franco R.F. Porphyria cutanea tarda in Brazilian patients: association with hemochromatosis C282Y mutation and hepatitis C virus infection. Am. J. Gastroenterol. 95 (2000) 3516-3521
134. Dereure O., Aguilar-Martinez P., Bessis D., Perney P., Vallat C., Guillot B., Blanc F., and Guilhou J.J. HFE mutations and transferrin receptor polymorphism analysis in porphyria cutanea tarda: a prospective study of 36 cases from southern France. Br. J. Dermatol. 144 (2001) 533-539
135. Tannapfel A., Stolzel U., Kostler E., Melz S., Richter M., Keim V., Schuppan D., and Wittekind C. C282Y and H63D mutation of the hemochromatosis gene in German porphyria cutanea tarda patients. Virchows Arch. 439 (2001) 1-5
136. Hift R.J., Corrigall A.V., Hancock V., Kannemeyer J., Kirsch R.E., and Meissner P.N. Porphyria cutanea tarda: the etiological importance of mutations in the HFE gene and viral infection is population-dependent. Cell. Mol. Biol. (Noisy-le-grand). 48 (2002) 853-859
137. Lamoril J., Andant C., Gouya L., Malonova E., Grandchamp B., Martasek P., Deybac J.C., and Puy H. Hemochromatosis (HFE) and transferrin receptor-1 (TFRC1) genes in sporadic porphyria cutanea tarda (sPCT). Cell. Mol. Biol. (Noisy-le-grand). 48 (2002) 33-41
138. Chiaverini C., Halimi G., Ouzan D., Halfon P., Ortonne J.P., and Lacour J.P. Porphyria cutanea tarda, C282Y, H63D and S65C HFE gene mutations and hepatitis C infection: a study from southern France. Dermatology 206 (2003) 212-216
139. Nagy Z., Koszo F., Par A., Emri G., Horkay I., Horanyi M., Karadi O., Rumi Jr. G., Morvay M., Varga V., Dobozy A., and Mozsik G. Hemochromatosis (HFE) gene mutations and hepatitis C virus infection as risk factors for porphyria cutanea tarda in Hungarian patients. Liver Int. 24 (2004) 16-20
140. Gonzalez-Hevilla M., de Salamanca R.E., Morales P., Martinez-Laso J., Fontanellas A., Castro M.J., Rojo R., Moscoso J., Zamora J., Serrano-Vela J.I., and Arnaiz-Villena A. Human leukocyte antigen haplotypes and HFE mutations in Spanish hereditary hemochromatosis and sporadic porphyria cutanea tarda. J. Gastroenterol. Hepatol. 20 (2005) 456-462
141. Frank J., Poblete-Gutierrez P., Weiskirchen R., Gressner O., Merk H.F., and Lammert F. Hemochromatosis gene sequence deviations in German patients with porphyria cutanea tarda. Physiol. Res. 55 Suppl 2 (2006) S75-83
142. Toll A., Celis R., Ozalla M.D., Bruguera M., Herrero C., and Ercilla M.G. The prevalence of HFE C282Y gene mutation is increased in Spanish patients with porphyria cutanea tarda without hepatitis C virus infection. J. Eur. Acad. Dermatol. Venereol. 20 (2006) 1201-1206
143. Sampietro M., Piperno A., Lupica L., Arosio C., Vergani A., Corbetta N., Malosio I., Mattioli M., Fracanzani A.L., Cappellini M.D., Fiorelli G., and Fargion S. High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda. Hepatology 27 (1998) 181-184
144. Sinclair P.R., Gorman N., Walton H.S., Bement W.J., Sinclair J.F., Gerhard G.S., Szakacs J.G., Andrews N.C., and Levy J.E. Uroporphyria in Hfe mutant mice given 5-aminolevulinate: a new model of Fe-mediated porphyria cutanea tarda. Hepatology 33 (2001) 406-412
145. Sinclair P.R., Gorman N., Trask H.W., Bement W.J., Szakacs J.G., Elder G.H., Balestra D., Sinclair J.F., and Gerhard G.S. Uroporphyria caused by ethanol in Hfe(-/-) mice as a model for porphyria cutanea tarda. Hepatology 37 (2003) 351-358
146. Gorman N., Trask H.W., Bement W.J., Szakacs J.G., Elder G.H., Balestra D., Jacobs N.J., Jacobs J.M., Sinclair J.F., Gerhard G.S., and Sinclair P.R. Genetic factors influence ethanol-induced uroporphyria in Hfe(-/-) mice. Hepatology 40 (2004) 942-950
147. Franklin M.R., Phillips J.D., and Kushner J.P. Uroporphyria in the uroporphyrinogen decarboxylase-deficient mouse: interplay with siderosis and polychlorinated biphenyl exposure. Hepatology 36 (2002) 805-811
148. Phillips J.D., Bergonia H.A., Reilly C.A., Franklin M.R., and Kushner J.P. A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 5079-5084